BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 19014961)

  • 1. Nongenomic activation of phosphatidylinositol 3-kinase signaling by thyroid hormone receptors.
    Furuya F; Lu C; Guigon CJ; Cheng SY
    Steroids; 2009 Jul; 74(7):628-34. PubMed ID: 19014961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear receptor corepressor is a novel regulator of phosphatidylinositol 3-kinase signaling.
    Furuya F; Guigon CJ; Zhao L; Lu C; Hanover JA; Cheng SY
    Mol Cell Biol; 2007 Sep; 27(17):6116-26. PubMed ID: 17606624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel functions of thyroid hormone receptor mutants: beyond nucleus-initiated transcription.
    Furuya F; Ying H; Zhao L; Cheng SY
    Steroids; 2007 Feb; 72(2):171-9. PubMed ID: 17169389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone beta receptor.
    Furuya F; Hanover JA; Cheng SY
    Proc Natl Acad Sci U S A; 2006 Feb; 103(6):1780-5. PubMed ID: 16446424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer.
    Furuya F; Lu C; Willingham MC; Cheng SY
    Carcinogenesis; 2007 Dec; 28(12):2451-8. PubMed ID: 17660507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel non-genomic signaling of thyroid hormone receptors in thyroid carcinogenesis.
    Guigon CJ; Cheng SY
    Mol Cell Endocrinol; 2009 Sep; 308(1-2):63-9. PubMed ID: 19549593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer.
    Guigon CJ; Zhao L; Willingham MC; Cheng SY
    Oncogene; 2009 Jan; 28(4):509-17. PubMed ID: 18997818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of beta-catenin by a novel nongenomic action of thyroid hormone beta receptor.
    Guigon CJ; Zhao L; Lu C; Willingham MC; Cheng SY
    Mol Cell Biol; 2008 Jul; 28(14):4598-608. PubMed ID: 18474620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of phosphatidylinositol 3-kinase signaling promotes aberrant pituitary growth in a mouse model of thyroid-stimulating hormone-secreting pituitary tumors.
    Lu C; Willingham MC; Furuya F; Cheng SY
    Endocrinology; 2008 Jul; 149(7):3339-45. PubMed ID: 18356276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thyroid hormone induces rapid activation of Akt/protein kinase B-mammalian target of rapamycin-p70S6K cascade through phosphatidylinositol 3-kinase in human fibroblasts.
    Cao X; Kambe F; Moeller LC; Refetoff S; Seo H
    Mol Endocrinol; 2005 Jan; 19(1):102-12. PubMed ID: 15388791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extranuclear signaling of mutated thyroid hormone receptors in promoting metastatic spread in thyroid carcinogenesis.
    Lu C; Cheng SY
    Steroids; 2011 Aug; 76(9):885-91. PubMed ID: 21473875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel oncogenic actions of TRbeta mutants in tumorigenesis.
    Guigon CJ; Cheng SY
    IUBMB Life; 2009 May; 61(5):528-36. PubMed ID: 19391168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thyroid hormone receptor mutations and disease: insights from knock-in mouse models.
    Cheng SY
    Expert Rev Endocrinol Metab; 2007 Jan; 2(1):47-57. PubMed ID: 30743748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AKT activation promotes metastasis in a mouse model of follicular thyroid carcinoma.
    Kim CS; Vasko VV; Kato Y; Kruhlak M; Saji M; Cheng SY; Ringel MD
    Endocrinology; 2005 Oct; 146(10):4456-63. PubMed ID: 16002527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thyroid hormone receptor beta mutants: Dominant negative regulators of peroxisome proliferator-activated receptor gamma action.
    Araki O; Ying H; Furuya F; Zhu X; Cheng SY
    Proc Natl Acad Sci U S A; 2005 Nov; 102(45):16251-6. PubMed ID: 16260719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenic mutations of thyroid hormone receptor β.
    Park JW; Zhao L; Willingham M; Cheng SY
    Oncotarget; 2015 Apr; 6(10):8115-31. PubMed ID: 25924236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular aspects of thyroid hormone actions.
    Cheng SY; Leonard JL; Davis PJ
    Endocr Rev; 2010 Apr; 31(2):139-70. PubMed ID: 20051527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An unliganded thyroid hormone beta receptor activates the cyclin D1/cyclin-dependent kinase/retinoblastoma/E2F pathway and induces pituitary tumorigenesis.
    Furumoto H; Ying H; Chandramouli GV; Zhao L; Walker RL; Meltzer PS; Willingham MC; Cheng SY
    Mol Cell Biol; 2005 Jan; 25(1):124-35. PubMed ID: 15601836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathological Interactions Between Mutant Thyroid Hormone Receptors and Corepressors and Their Modulation by a Thyroid Hormone Analogue with Therapeutic Potential.
    Harrus D; Déméné H; Vasquez E; Boulahtouf A; Germain P; Figueira AC; Privalsky ML; Bourguet W; le Maire A
    Thyroid; 2018 Dec; 28(12):1708-1722. PubMed ID: 30235988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of the phosphatidylinositol 3-kinase, Akt/protein kinase B, FRAP/mammalian target of rapamycin, and ribosomal S6 kinase 1 signaling pathways by thyroid-stimulating hormone (TSH) and stimulating type TSH receptor antibodies in the thyroid gland.
    Suh JM; Song JH; Kim DW; Kim H; Chung HK; Hwang JH; Kim JM; Hwang ES; Chung J; Han JH; Cho BY; Ro HK; Shong M
    J Biol Chem; 2003 Jun; 278(24):21960-71. PubMed ID: 12668683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.